Aclaris Therapeutics, Inc. (ACRS) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US00461U1051
Aclaris Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 7.83 m USD |
| Gross profit | 5.74 m USD |
| Operating income | -76.38 m USD |
| EBIT | -72.56 m USD |
| Net income | -64.92 m USD |
| Diluted EPS – continuing operations | -0.53 USD |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
More stocks
- Shinyoung Securities Co. Ltd. (001720.KS)
- Silex Systems Ltd (SLX.AX)
- PARK OHIO HOLDINGS CORP (PKOH)
- T1 Energy Inc. (TE)
- Shenzhen Weiguang Biological Products Co Ltd (002880.SZ)
- SANFILIPPO JOHN B & SON INC (JBSS)
- Chicony Power Technology Co Ltd (6412.TW)
- Midland States Bancorp, Inc. (MSBI)
- Associated Capital Group, Inc. (ACGP)
- Ronglian Group Ltd (002642.SZ)
- Zhongyeda Electric Co Ltd (002441.SZ)
- Inspur Software Co Ltd (600756.SS)
Not investment advice. All data without warranty, price as of 06.11.2026. Details in the risk notice.